Office of Inspector General, Department of Health and Human Services USA, “The Globalization of Clinical Trials,” 2001 OEI 01-00-00190.
2.
MarshallP. A., “The Relevance of Culture for Informed Consent in U.S. – funded International Health Research,” Commissioned Paper, National Bioethics Advisory Commission, Ethical and Policy Issues in International Research: Clinical Trials in Developing Countries, vol. 2 (Bethesda: US Dept of Commerce, Technology Administration, National Technical Information Service, 2001).
3.
“The Nuremberg Code,”Trials of War Criminals before the Military Tribunals under Control Council Law10, vol 2 (Washington, DC: US Government Printing Office, 1949): 181–182.
4.
The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, The Belmont Report (Washington, DC: US Government Printing Offices, 1978).
5.
World Medical Association (WMA), The Declaration of Helsinki, October 2000, available at <www.wma.net> (last visited June 13, 2005).
6.
CarlingA., “Exploitation,”Encyclopedia of Applied Ethics, vol. 2 (New York: Academic Press, 1998): 219–232; ArnesonR., “Exploitation,” in BeckerL. C.BeckerC. B., eds., Encyclopedia of Ethics (New York: Garland Publishing, 1992): 350–352.
7.
RoemerJ. E., A General Theory of Exploitation and Class (Cambridge: Harvard University Press, 1982).
8.
The Participants in the 2001 Conference on Ethical Aspects of Research in Developing Countries, Moral Standards for Research in Developing Countries, “From ‘Reasonable Availability’ to ‘Fair Benefits,’”Hastings Center Report34 (2004): 17–27.
9.
Nuffield Council on Bioethics, The Ethics of Research Related to Health Care in Developing Countries, available at <www.nuffieldbioethics.org/publications> (last visited June 13, 2005).
10.
Office of Inspector General, Department of Health and Human Services USA, Recruiting Human Subjects: Pressures in Industry Sponsored Clinical Research, 2000. OEI-01-97-00195.
11.
KassN.HyderA. A., “Attitudes and Experiences of US and Developing Country Investigators Regarding US Human Subjects Regulations,”Commissioned Paper, National Bioethics Advisory Commission, Ethical and Policy Issues in International Research: Clinical Trials in Developing Countries, vol. 2 (Bethesda: US Dept of Commerce, Technology Administration, National Technical Information Service, 2001).
12.
Council for International Organizations of Medical Sciences (CIOMS), “International Ethical Guidelines for Biomedical Research Involving Human Subjects” (CIOMS: Geneva, 2002) at <http://www.cioms.ch/frame_guidelines_nov_2002.htm> (last visited June 17, 2005).
13.
UNAIDS guidance document, Ethical Considerations in HIV Preventive Vaccine Research, June 1991, at <www.unaids.org/publications/documents> (last visited June 13, 2005); GuenterD.EsparzaJ.MacklinR., “Ethical Considerations in International HIV Vaccine Trials: Summary of a Consultative Process Conducted by the Joint United Nations Programme on HIV/AIDS (UNAIDS),”Journal of Medical Ethics26 (2000): 37–43.
14.
Commission on Health Research for Development, Health Research: Essential Link to Equity in Development (Oxford: Oxford University Press, 1990); BenatarS. R.SingerP. A., “Beyond Helsinki: A Vision for Global Health Ethics,”British Medical Journal322 (2001): 747–748.
15.
NielsenK., “Global Justice, Capitalism and the Third World,” in AttfieldR.WilkinB., eds., International Justice and the Third World (London, New York: Routledge, 1992): At 28.
16.
RawlsJ., Theory of Justice (Cambridge, MA: Harvard University Press, 1971).
17.
BeitzC. R., “Justice and International Relations,” in BlockerH. G.SmithE. H., eds., John Rawls' Theory of Social Justice: An Introduction (Athens: Ohio University Press, 1980): At 232.
18.
LaveryJ. V., “Putting International Research Ethics Guidelines to Work for the Benefit of Developing Countries,”Yale Journal of Health Policy, Law and EthicsIV (2004): At 335.
19.
The Centers for Disease Control and Prevention, Syphilis Elimination: History in the Making, 2003, at <http://www.cdc.gov/stopsyphilis>.
20.
RadolfJ. D.SanchezP. J.SchulzK. F.MurphyF. K., “Congenital Syphilis,” in HolmesK. K.MardhP.SparlingP. F.LemonS. M.StammW. E.PiotP.WasserheitJ. N., eds., Sexually Transmitted Diseases (New York: McGraw Hill, 1999): 1168–1170.
21.
FitzgeraldD. W.BehetsF. M., “A Piece of my Mind: Beyond Folklore,”JAMA288 (2002): At 2791–2.
22.
BenatarS. R.SingerP. A., “Beyond Helsinki: A Vision for Global Health Ethics,”British Medical Journal322 (2001): 747–748.
23.
KolataG., “Companies Facing Ethical Issue as Drugs Are Tested Overseas,”New York Times, March 5, 2004, at 1.
24.
The Centers for Disease Control and Prevention, “Update: Outbreak of Poliomyelitis – Dominican Republic and Haiti 2000–2001,”JAMA286 (2001): At 2802.
25.
FitzgeraldD. W.PapeJ. W.WasserheitJ. N.CountsG. W.CoreyL., “Provision of Treatment in HIV-1 Vaccine Trials in Developing Countries,”Lancet362 (2003): 993–994.
See for example, the current controversies over Tenofovir prophylactic research. Editorial, “The Trials of Tenofovir Trials,”Lancet365 (2005): At 1111.
28.
GuptaR.CegielskiP.EspinalM. A.HenkensM.KimJ. Y.Lambregts-Van WeezenbeekC. S. B.LeeJ.RaviglioneM. C.SuarezP. G.VaraineF., “Increasing Transparency in Partnership for Health-introducing the Green Light Committee,”Tropical Medicine and International Health7 (2002): 970–976.
29.
MrazekM. F.MossialosE., “Stimulating Pharmaceutical Research and Development for Neglected Diseases,”Health Policy64 (2002): At 75–88.
30.
Gumucio DagronA., Making Waves: Stories of Participatory Communication for Social Change (New York: Rockefeller Foundation, 2001): 5–37.
31.
National Bioethics Advisory Commission, Ethical and Policy Issues in International Research: Clinical Trials in Developing Countries, vol. 1 (Bethesda: US Dept of Commerce, Technology Administration, National Technical Information Service, 2001).
32.
AnandS.DiderichsenF.EvansT.SchkolnikovV. M.WirthM., “Measuring Disparities in Health: Methods and Indicators,” in EvansT.WhiteheadM.DiderichsenF.BhuiyaA.WirthM., eds., Challenging Inequities in Health: From Ethics to Action (New York: Oxford Press, 2001): 48–68.